Healthcare / BiotechnologyKOSDAQ
$5250.00
-440.00 (-7.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-14.8B · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$478.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-96.3%
↓Gross Margin
100.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-75.7%
FCF CAGR
—
FCF margin
-20900.4%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $111.2M · net income $-27.36B · FCF $-23.24B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $111.2M | $111.2M | $654.5M | $110.0M | $7.73B |
| Net Income | $-27.36B | $-27.36B | $-5.69B | $8.86B | $-3.49B |
| EBITDA | $-26.47B | $-26.47B | $-4.63B | $9.90B | $-2.37B |
| EPS | -362.25 | -362.25 | -93.81 | -143.97 | -188.55 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -25185.3% | -25185.3% | -1921.2% | -10726.1% | -194.9% |
| Net Margin | -24605.1% | -24605.1% | -868.9% | 8058.2% | -45.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| Current Ratio | 5.39 | 5.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-23.24B | $-23.24B | $-14.81B | $-8.77B | $-15.39B |
| Returns | |||||
| ROE | -96.3% | -96.3% | -29.3% | -25.9% | 6.7% |
| Valuation | |||||
| P/B | 13.96 | 13.96 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -83.0% | -83.0% | 495.0% | -98.6% | — |
| EPS Growth | -286.1% | -286.1% | 34.8% | 23.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-93.81 → -362.25
Residual
-23.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.